175 related articles for article (PubMed ID: 30411431)
21. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
22. Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors.
Parise CA; Caggiano V
Breast Cancer Res Treat; 2017 Oct; 165(3):743-750. PubMed ID: 28689363
[TBL] [Abstract][Full Text] [Related]
23. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
[TBL] [Abstract][Full Text] [Related]
24.
Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
26. Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran.
Ansaripour A; Zendehdel K; Tadayon N; Sadeghi F; Uyl-de Groot CA; Redekop WK
PLoS One; 2018; 13(10):e0205079. PubMed ID: 30273393
[TBL] [Abstract][Full Text] [Related]
27. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
[TBL] [Abstract][Full Text] [Related]
28. Is the TNM staging system for breast cancer still relevant in the era of biomarkers and emerging personalized medicine for breast cancer - an institution's 10-year experience.
Orucevic A; Chen J; McLoughlin JM; Heidel RE; Panella T; Bell J
Breast J; 2015; 21(2):147-54. PubMed ID: 25600504
[TBL] [Abstract][Full Text] [Related]
29. A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
Risi E; Grilli A; Migliaccio I; Biagioni C; McCartney A; Guarducci C; Bonechi M; Benelli M; Vitale S; Biganzoli L; Bicciato S; Di Leo A; Malorni L
Breast Cancer Res Treat; 2018 Jul; 170(2):329-341. PubMed ID: 29564743
[TBL] [Abstract][Full Text] [Related]
30. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
31. Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2- breast cancer subtypes.
Parise CA; Caggiano V
Cancer Causes Control; 2019 May; 30(5):417-424. PubMed ID: 30879205
[TBL] [Abstract][Full Text] [Related]
32. Development and validation of a predictive model algorithm to identify anaphylaxis in adults with type 2 diabetes in U.S. administrative claims data.
Beachler DC; Taylor DH; Anthony MS; Yin R; Li L; Saltus CW; Li L; Shaunik A; Walsh KE; Rothman KJ; Johannes CB; Aroda VR; Carr W; Goldberg P; Accardi A; O'Shura JS; Sharma K; Juhaeri J; Lanes S; Wu C
Pharmacoepidemiol Drug Saf; 2021 Jul; 30(7):918-926. PubMed ID: 33899314
[TBL] [Abstract][Full Text] [Related]
33. Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008.
Cossetti RJ; Tyldesley SK; Speers CH; Zheng Y; Gelmon KA
J Clin Oncol; 2015 Jan; 33(1):65-73. PubMed ID: 25422485
[TBL] [Abstract][Full Text] [Related]
34. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
35. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
36. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
[TBL] [Abstract][Full Text] [Related]
37. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
38. Estrogen receptor positive operable breast cancer: does menopausal status impact on HER2 and progesterone receptor status?
Wang N; Wang B; Wang Y; Hu J
Breast; 2011 Dec; 20(6):519-24. PubMed ID: 21700456
[TBL] [Abstract][Full Text] [Related]
39. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
40. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.
Burton T; Byfield SD; Smith GL; Zanotti G; Bell TJ; Perkins JJ; Horblyuk R; Teitelbaum A
Curr Med Res Opin; 2016 Aug; 32(8):1417-23. PubMed ID: 27074160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]